Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02111499
Recruitment Status : Completed
First Posted : April 11, 2014
Last Update Posted : June 9, 2014
Sponsor:
Collaborator:
proDERM GmbH
Information provided by (Responsible Party):
Almirall, S.A.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Clinical investigation of anti-psoriatic efficacy and atrophy

Condition or disease Intervention/treatment Phase
Psoriasis Drug: LAS41004-IMP1 Drug: LAS41004 IMP2 Drug: LAS41004 IMP3 Drug: LAS41004 IMP4 Drug: LAS41004 IMP6 Drug: LAS41004 IMP5 Phase 1 Phase 2

Detailed Description:

In this trial three concentrations of bexarotene in combination with a fixed concentration of betamethasone dipropionate, as well as monotherapy with bexarotene, will be investigated regarding their efficacy, tolerability and safety in patients with mild to moderate plaque psoriasis and will be compared with the vehicle and an active comparator.

Since a side effect of the application of corticosteroids is skin atrophy, additionally three non-lesional test areas (not affected by psoriasis) on the volar forearm will be treated with the active reference product, one of the fixed combinations and the vehicle. Skin atrophy will be investigated by visual assessment and ultrasound at these test areas

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis
Study Start Date : March 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: formulation 1
topical treatment, once daily for 4 weeks
 Drug: LAS41004-IMP1
daily topical application

Drug: LAS41004 IMP2
daily topical application

Drug: LAS41004 IMP3
daily topical application

Drug: LAS41004 IMP4
daily topical application

Drug: LAS41004 IMP6
daily topical application

Drug: LAS41004 IMP5
once daily, topical
Experimental: formulation 2
topical treatment, once daily for 4 weeks
 Drug: LAS41004-IMP1
daily topical application

Drug: LAS41004 IMP2
daily topical application

Drug: LAS41004 IMP3
daily topical application

Drug: LAS41004 IMP4
daily topical application

Drug: LAS41004 IMP6
daily topical application

Drug: LAS41004 IMP5
once daily, topical
Experimental: formulation 3
topical treatment, once daily for 4 weeks
 Drug: LAS41004-IMP1
daily topical application

Drug: LAS41004 IMP2
daily topical application

Drug: LAS41004 IMP3
daily topical application

Drug: LAS41004 IMP4
daily topical application

Drug: LAS41004 IMP6
daily topical application

Drug: LAS41004 IMP5
once daily, topical
Experimental: formulation 4
topical treatment,once daily for 4 weeks
 Drug: LAS41004-IMP1
daily topical application

Drug: LAS41004 IMP2
daily topical application

Drug: LAS41004 IMP3
daily topical application

Drug: LAS41004 IMP4
daily topical application

Drug: LAS41004 IMP6
daily topical application

Drug: LAS41004 IMP5
once daily, topical
Placebo Comparator: formulation 5
topical treatment, once daily for 4 weeks
 Drug: LAS41004-IMP1
daily topical application

Drug: LAS41004 IMP2
daily topical application

Drug: LAS41004 IMP3
daily topical application

Drug: LAS41004 IMP4
daily topical application

Drug: LAS41004 IMP6
daily topical application

Drug: LAS41004 IMP5
once daily, topical
Active Comparator: formulation 6
topical treatment, once daily for 4 weeks
 Drug: LAS41004-IMP1
daily topical application

Drug: LAS41004 IMP2
daily topical application

Drug: LAS41004 IMP3
daily topical application

Drug: LAS41004 IMP4
daily topical application

Drug: LAS41004 IMP6
daily topical application

Drug: LAS41004 IMP5
once daily, topical


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Area under the curve, AUC, of the width of the echo-lucent band based on sonography measurements [ Time Frame: day 1 vs day 29 ]
    The primary objective is to gain evidence suggesting efficacy of the investigational products in the treatment of plaque-type psoriasis as assessed by the AUC of the width of the echo-lucent band


Secondary Outcome Measures :
  1. erythema and induration [ Time Frame: day 1 vs day 29 ]
    investigation of the individual scores for erythema and induration

  2. local skin tolerability [ Time Frame: every day for 28 days ]
    Safety investigation of tolerability parameters assessed by a dermatologist

  3. atrophy [ Time Frame: day1 vs day 29 ]
    investigation of skin atrophy assessments on non-lesional test areas

  4. assessment of (serious) Adverse Events [ Time Frame: from baseline to day 29 ]
    Daily record will be performed and - if needed - causality and severity assessed


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • 18 to 75 years of age
  • Men and women with skin type I to IV (Fitzpatrick 1974).
  • Suffering from mild to moderate plaque psoriasis of at least 6 months duration that is amenable to local therapy.

  • With at least one stable psoriatic plaque in an area sufficient for product application meeting the following criteria:

    • Located at the trunk and/or the extremities (plaques located on the head, palms, or soles of the feet, intertriginous or genitoanal areas are not suitable).
    • Plaques with a clinical score of the parameter erythema and or induration of ≥ 2 for each sign at the screening visit. At Day 1 each parameter has to be scored ≥ 2.
    • Where more than one plaque is to be used, plaques should be comparable, with at least "2" in each score for erythema and induration.
    • • Body surface area (BSA) involvement < 10 %.
  • Prepared to give written informed consent specific to the trial, before any assessment is performed.
  • • In the case of women of childbearing potential using reliable methods of contraception which result in a low failure rate i.e. less than 1% per year (e.g. contraceptive implants or injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner). During the study an additional barrier method (e.g. condoms) should be used. Non-childbearing potential is defined as surgical sterilization (hysterectomy, ovariectomy or tubal ligation), postmenopausal status (continuous amenorrhea of at least 2 years).
  • In the case of men with partners of childbearing potential willingness of using condoms during the study conduct and 1 month after end of treatment.

Main Exclusion Criteria:

  • • Patients who need systemic treatment for their psoriasis.

    • Severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,
    • Systemic treatment (see table below):

Corticosteroids, antibiotics 4 weeks prior to trial Day 1 and during conduct of trial Retinoids Ciclosporin Methotrexate Fumaric acid esters 3 months prior to trial Day 1 and during conduct of trial Anti-inflammatory substances, NSAIDs 2 weeks prior to trial Day 1 and during conduct of trial Biologics 6 months prior to trial Day 1 and during conduct of trial

  • Topical treatment of all other body regions with corticosteroids or immunosuppressants where more than 20 % of the body surface area is treated.
  • Diseases:

Significant skin infections caused by bacteria, viruses or fungi, including but not limited to tuberculosis, syphilis or varicella zoster infection Parasitic infections

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02111499


Locations
Layout table for location information
Germany
proDERM GmbH
Schenefeld, Schleswig-Holstein, Germany, 22869
Sponsors and Collaborators
Almirall, S.A.
proDERM GmbH
Investigators
Layout table for investigator information
Principal Investigator: Kirstin Deuble-Bente, Dr med proDERM GmbH
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Almirall, S.A.
ClinicalTrials.gov Identifier: NCT02111499    
Other Study ID Numbers: H553000-1308
2013-003754-24 ( EudraCT Number )
First Posted: April 11, 2014    Key Record Dates
Last Update Posted: June 9, 2014
Last Verified: June 2014
Keywords provided by Almirall, S.A.:
psoriasis plaque test
topical application
atrophy measure
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases